- Home
- BBIO vs ITIC Comparison
BBIO vs ITIC Comparison
Compare BBIO & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ITIC
- Stock Information
- Founded
- BBIO 2015
- ITIC 1972
- Country
- BBIO United States
- ITIC United States
- Employees
- BBIO N/A
- ITIC N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ITIC Specialty Insurers
- Sector
- BBIO Health Care
- ITIC Finance
- Exchange
- BBIO Nasdaq
- ITIC Nasdaq
- Market Cap
- BBIO 6.7B
- ITIC 437.8M
- IPO Year
- BBIO 2019
- ITIC N/A
- Fundamental
- Price
- BBIO $34.67
- ITIC $238.00
- Analyst Decision
- BBIO Strong Buy
- ITIC
- Analyst Count
- BBIO 12
- ITIC 0
- Target Price
- BBIO $57.09
- ITIC N/A
- AVG Volume (30 Days)
- BBIO 3.2M
- ITIC 10.6K
- Earning Date
- BBIO 04-29-2025
- ITIC 05-08-2025
- Dividend Yield
- BBIO N/A
- ITIC 6.56%
- EPS Growth
- BBIO N/A
- ITIC 18.56
- EPS
- BBIO N/A
- ITIC 15.69
- Revenue
- BBIO $127,415,000.00
- ITIC $261,183,000.00
- Revenue This Year
- BBIO $13.67
- ITIC N/A
- Revenue Next Year
- BBIO $118.02
- ITIC N/A
- P/E Ratio
- BBIO N/A
- ITIC $14.55
- Revenue Growth
- BBIO N/A
- ITIC 15.26
- 52 Week Low
- BBIO $21.62
- ITIC $146.41
- 52 Week High
- BBIO $39.47
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- BBIO 49.67
- ITIC 56.40
- Support Level
- BBIO $33.92
- ITIC $237.00
- Resistance Level
- BBIO $39.16
- ITIC $244.00
- Average True Range (ATR)
- BBIO 1.43
- ITIC 4.68
- MACD
- BBIO -0.16
- ITIC 1.34
- Stochastic Oscillator
- BBIO 31.05
- ITIC 78.68
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.